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Background: Akt is a serine/threonine kinase that plays an important role in tumorigenesis and influences
prognosis in several cancers. However, its importance in oral squamous cell carcinomas (OSCC) has not
been elucidated.
Aim: To investigate the association between the expression of activated Akt, clinicopathological factors,
and E-cadherin, PCNA (proliferating cell nuclear antigen), and VEGF (vascular endothelial growth factor)
expression to verify the validity of Akt as a prognostic factor in OSCC.
Methods: Phosphorylated Akt (p-Akt), E-cadherin, PCNA, and VEGF expression were assessed
immunohistochemically in 84 OSCCs. The results were analysed in relation to clinicopathological factors.
Results: p-Akt was expressed in 29 cases. It was significantly correlated with lymph node metastasis, TNM
stage, and E-cadherin expression. Univariate analysis showed that p-Akt expression, E-cadherin
expression, PCNA expression, differentiation, tumour size, lymph node metastasis, TNM stage, and
recurrence correlated with prognosis. Multivariate analysis showed that p-Akt expression is an
independent prognostic factor in patients with OSCC.
Conclusions: This study revealed that Akt activation is a significant prognostic indicator for OSCC and is
correlated with E-cadherin expression. The inhibition of Akt is a possible molecular approach to the
treatment of OSCC.
O
ral cancer is the sixth most common cancer world-
wide. The most common type of oral cancer is
squamous cell carcinoma, which accounts for almost
nine out of 10 oral malignancies.1 The prognostic evaluation
and decisions on treatment strategy are mainly based on the
TNM stage.2 Despite progress in treatment modalities over
the past few decades, oral cancer still has a poor survival rate,
with a high incidence of metastasis.3 4 Oncogenes, tumour
suppressor genes,5–7 cell proliferation markers,8 angiogenesis,9
and cell adhesion molecules10 11 have been studied as
potential tools to predict the prognosis of an individual with
oral squamous cell carcinoma (OSCC).
‘‘Despite progress in treatment modalities over the past
few decades, oral cancer still has a poor survival rate, with
a high incidence of metastasis’’
The oncogenic serine/threonine kinase Akt1 (also known
as PKB) is a downstream effector of phosphatidylinositol 3-
kinase and is frequently activated in human cancer.12 The
gene for the closely related Akt2 is amplified and over-
expressed in ovarian, pancreatic, breast, and follicular thyroid
carcinomas.13–17 In addition, total Akt kinase activity is
increased in non-small cell lung cancer, squamous cell
carcinomas of the oral cavity, breast carcinoma, and prostate
carcinoma.18–20 Akt activation contributes to tumorigenesis.
The main biological consequences of Akt activation that are
relevant to cancer cell growth can be classified loosely into
three categories: survival, proliferation (increased cell num-
ber), and growth (increased cell size).21
Akt activation is also associated with enhanced tumour cell
invasion. Akt enhances invasiveness of pancreatic carcinoma
cells via upregulation of insulin-like growth factor I,22 and it
increases the secretion of matrix metalloproteinases 2 and 9
in immortalised mammary epithelial cells and ovarian
carcinomas.23 24 Activation of the Akt pathway in cancer cells
leads to epithelial–mesenchymal transition and invasion in
vivo. Akt induced epithelial–mesenchymal transition involves
downregulation of E-cadherin, which appears to result from
upregulation of the transcription repressor SNAIL.25
Akt has additional effects on tumour induced angiogenesis
that are mediated, in part, through hypoxia inducible factor
1a and vascular endothelial growth factor (VEGF).21
There are few reports that have examined the relation
between activated Akt expression, clinicopathological factors,
and Akt related gene expression in OSCC.
The purpose of our study was to clarify the relation
between activated Akt expression, clinicopathological factors,
and the expression of E-cadherin, proliferating cell nuclear
antigen (PCNA), and VEGF. Accordingly, the potential value
of Akt as a prognostic indicator of survival was assessed.
MATERIALS AND METHODS
Patients and tumour samples
Eighty four patients (62 men and 22 women) with OSCC
were examined by immunohistochemistry. All tumours were
surgically removed at the department of oral and maxillofa-
cial surgery, Seoul National University Dental Hospital, South
Korea, between 1992 and 2001. The age of the patients
ranged from 27 to 93 years, with a mean of 59.0 years.
Clinical data obtained from patient charts included age, sex,
smoking habits, alcohol consumption, TNM stage, and
recurrence. Tumours were staged according to the current
TNM classification as recommended by the AJCC.26 Tumours
were re-reviewed by two pathologists to determine the
histological grade (well differentiated, moderately differen-
tiated, or poorly differentiated). Survival was calculated from
Abbreviations: LI, labelling index; OSCC, oral squamous cell
carcinoma; PBS, phosphate buffered saline; p-Akt, phosphorylated Akt;




 group.bmj.com on March 10, 2010 - Published by jcp.bmj.comDownloaded from 
Table 1 Summary of the clinicopathological features and p-Akt, E-cadherin, VEGF, and PCNA expression
Case Age Sex Sm. Al. Dif. TNM Stage Rec. p-AKT E-cadherin VEGF PCNA I DOF/Status
1 41 M Yes Yes Well T1N0M0 I Neg. Neg. Neg. 68 56/L
2 66 M No No Well T2N0M0 II Pos. Neg. Pos. 50 44/L
3 45 M No Yes Well T4N1M0 IV Neg. Pos. Pos. 31 44/L
4 67 M Yes No Well T4N1M0 IV Neg. Neg. Neg. 57 7/D
5 66 F No No Well T1N0M0 I Neg. Pos. Pos. 36 54/L
6 82 F No No Well T4N1M0 IV Pos. Neg. Pos. 35 8/D
7 58 F No No Well T1N0M0 I Neg. Neg. Neg. 51 52/L
8 60 M No Yes Well T1N0M0 I R Neg. Pos. Neg. 11 41/L
9 55 M Yes Yes Mod. T1N0M0 I R Neg. Neg. Neg. 33 68/L
10 53 M Yes No Mod. T1N0M0 I Neg. Neg. Pos. 40 51/L
11 52 M Yes No Well T2N0M0 II R Pos. Neg. Pos. 41 22/D
12 63 M Yes Yes Well T2N1M0 IV Pos. Neg. Pos. 71 18/D
13 45 M No Yes Well T1N0M0 I Neg. Pos. Pos. 40 38/L
14 52 M No Yes Well T1N0M0 I Neg. Neg. Pos. 76 38/L
15 57 F No No Well T4N1M1 IV Neg. Pos. Pos. 39 49/L
16 39 F No No Well T2N0M0 II Pos. Neg. Pos. 53 49/L
17 66 M Yes No Mod. T4N0M0 IV Pos. Neg. Pos. 70 48/L
18 52 F No No Well T1N0M0 I Neg. Pos. Pos. 77 34/L
19 52 F No No Poor T2N0M0 II Pos. Neg. Pos. 73 5/D
20 66 F No No Well T1N0M0 I Neg. Pos. Pos. 54 47/L
21 64 M Yes Yes Mod. T2N0M0 II R Neg. Neg. Pos. 40 9/D
22 67 M Yes Yes Mod. T2N0M0 II Neg. Neg. Pos. 50 47/L
23 64 M Yes Yes Well T2N0M0 II Neg. Pos. Pos. 45 46/L
24 72 M No No Mod. T2N0M0 II R Pos. Neg. Pos. 62 24/D
25 39 M Yes Yes Well T2N0M0 II Neg. Pos. Neg. 62 45/L
26 45 M Yes Yes Well T2N1M0 IV Neg. Pos. Pos. 48 45/L
27 69 M Yes Yes Well T1N0M0 I Pos. Neg. Pos. 28 45/L
28 52 F No No Mod. T2N0M0 II Neg. Neg. Neg. 70 44/L
29 66 M No No Well T1N0M0 I Neg. Pos. Neg. 29 32/L
30 56 M No Yes Mod. T4N1M0 IV R Neg. Pos. Neg. 68 42/L
31 64 M No No Well T2N1M0 III R Pos. Neg. Pos. 52 14/D
32 78 F No No Well T2N1M0 III R Pos. Neg. Pos. 58 8/D
33 58 M Yes Yes Mod. T4N1M0 IV R Pos. Neg. Pos. 69 16/D
34 76 F No No Well T4N0M0 IV R Neg. Pos. Neg. 11 37/L
35 65 M No No Well T4N1M0 IV Neg. Pos. Pos. 88 5/D
36 64 M No No Well T2N0M0 II Neg. Pos. Pos. 80 32/L
37 65 M Yes Yes Well T3N1M0 III R Neg. Neg. Pos. 72 4/D
38 60 M Yes Yes Poor T4N0M0 IV R Neg. Pos. Neg. 71 9/D
39 66 M Yes Yes Well T1N1M0 IV R Pos. Neg. Pos. 18 7/D
40 68 M No No Mod. T4N1M0 IV Pos. Pos. Pos. 77 30/L
41 55 M No No Mod. T4N1M0 IV R Pos. Neg. Pos. 67 9/D
42 67 M Yes Yes Well T4N1M0 IV Pos. Neg. Pos. 95 13/D
43 27 M Yes Yes Well T1N0M0 I Neg. Neg. Neg. 66 28/L
44 57 M Yes Yes Well T1N0M0 I Neg. Pos. Pos. 49 32/L
45 60 M Yes Yes Well T1N1M1 III Neg. Pos. Pos. 57 28/L
46 72 F No No Well T4N0M0 IV Neg. Pos. Neg. 69 27/L
47 93 M No No Poor T2N0M0 II Neg. Pos. Pos. 56 26/L
48 67 F No No Well T2N1M0 III R Pos. Neg. Neg. 67 27/L
49 49 M No No Well T1N0M0 I Neg. Pos. Neg. 76 26/L
50 82 M No No Mod. T4N0M0 IV Neg. Pos. Pos. 57 25/L
51 66 F No No Well T1N0M0 I Neg. Neg. Neg. 42 40/L
52 58 M Yes Yes Well T4N0M0 IV Neg. Pos. Pos. 68 24/L
53 70 M No No Well T2N0M0 II R Neg. Pos. Pos. 76 2/D
54 53 F No No Well T1N1M0 III R Neg. Neg. Pos. 51 16/L
55 54 F No No Well T2N0M0 II R Neg. Neg. Pos. 59 30/L
56 45 M Yes Yes Mod. T4N1M1 IV R Neg. Neg. Pos. 39 26/L
57 28 F No No Well T1N0M0 I Neg. Neg. Pos. 54 75/L
58 34 M No No Well T4N1M0 IV Pos. Neg. Pos. 70 104/L
59 58 M Yes Yes Mod. T4N0M0 IV R Pos. Neg. Pos. 51 16/D
60 71 M Yes Yes Well T1N0M0 I Neg. Neg. Pos. 82 13/D
61 46 M No No Well T4N0M0 IV R Neg. Pos. Neg. 31 8/D
62 65 M Yes Yes Well T2N0M0 II Neg. Pos. Neg. 66 80/L
63 55 M No No Well T4N0M0 IV R Pos. Neg. Pos. 62 92/L
64 39 F Yes No Well T4N1M0 IV R Neg. Neg. Pos. 42 26/D
65 46 M Yes Yes Well T1N0M0 I Pos. Pos. Neg. 39 70/L
66 84 M Yes Yes Mod. T4N1M0 IV Pos. Neg. Neg. 81 6/D
67 55 F No No Well T1N0M0 I R Neg. Pos. Pos. 81 134/L
68 63 F No No Mod. T4N1M0 IV Neg. Pos. Pos. 31 17/D
69 58 M Yes Yes Mod. T4N0M0 IV Neg. Pos. Pos. 71 27/D
70 57 M Yes Yes Well T4N1M0 IV R Pos. Neg. Pos. 68 13/D
71 62 M Yes Yes Well T1N0M0 I Neg. Pos. Neg. 68 66/L
72 55 F No No Well T4N0M0 IV R Pos. Pos. Pos. 71 14/D
73 69 M Yes Yes Well T1N0M0 I R Neg. Pos. Pos. 74 66/L
74 50 M Yes Yes Well T4N0M0 IV Neg. Pos. Neg. 7 62/L
75 63 F No No Well T1N0M0 I Neg. Pos. Pos. 59 25/D
76 64 M Yes Yes Well T2N0M0 II Pos. Neg. Pos. 77 5/D
77 73 M Yes Yes Well T2N0M0 II R Neg. Pos. Pos. 62 38/D
78 45 M No No Well T4N1M1 IV R Pos. Neg. Neg. 57 62/L
79 59 M Yes Yes Mod. T4N0M0 IV Pos. Pos. Neg. 55 8/D
80 55 M No Yes Well T1N0M0 I Neg. Pos. Neg. 68 61/L
81 58 M Yes Yes Poor T4N1M0 IV Pos. Neg. Neg. 93 6/D
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the date of diagnosis until the date of death or last follow up
(table 1).
Immunohistochemistry
Immunohistochemical staining was performed using the
streptavidin–biotin–peroxidase complex method. Sections
(4 mm thick) were cut from each paraffin wax block,
dewaxed, and incubated for 15 minutes in a methanol
solution containing 3% H2O2 to block endogenous peroxidase
activity. For phosphorylated Akt (p-Akt), E-cadherin, and
VEGF staining, the slides were placed in 0.01M citrate buffer
(pH 6.0) and heated in a 500 W microwave oven for two five
minute periods. After washing with phosphate buffered
saline (PBS), sections were incubated in 10% normal rabbit
serum for 30 minutes to reduce non-specific antibody
binding. The primary antibodies used were: monoclonal
rabbit antihuman p-Akt (Ser 473; Cell Signaling Technology,
Beverley, Massachusetts, USA) at a dilution of 1/50;
monoclonal mouse antihuman VEGF (clone G153-694;
Pharmingen, San Diego, California, USA) at a dilution of 1/
400; monoclonal mouse antihuman E-cadherin (G-10; Santa
Cruz Biotechnology, Santa Cruz, California, USA) at a
dilution of 1/200; and monoclonal mouse antihuman PCNA
(P-10; Dako, Glostrup, Denmark) at a dilution of 1/100. All
sections were incubated for one hour at room temperature,
except for the Akt sections, which were incubated overnight
at 4 C̊. After being washed with PBS, sections were incubated
with biotinylated goat antirabbit IgG for 30 minutes. They
were then washed three times with PBS, treated with
streptavidin–peroxidase reagent for 30 minutes, and re-
washed with PBS three times. The reactions were visualised
with diaminobenzidine (Dako) as chromogen and sections
were counterstained with Mayer’s haematoxylin. Normal
mouse and rabbit IgG were substituted for each primary
antibody as negative controls.
Evaluation of immunohistochemical results
The cutoff points were based on the distribution of staining
results or the results of other studies in the literature, because
clear biological criteria are not available. For p-Akt the cutoff
point was 0–20% v . 20%.27 For E-cadherin, expression was
defined as positive when at least 50% of the cells showed
membrane staining.28 For VEGF, the cutoff point was 20%.29
For PCNA, nuclei from over 1000 tumour cells were counted
in the five to eight random fields chosen for each sample and
the count was expressed as the percentage of PCNA positive
cells (PCNA labelling index; LI).
The slides were assessed by consensus between two
investigators who had no prior knowledge of the correspond-
ing clinicopathological data.
Statistical analysis
Relations between p-Akt, E-cadherin, and VEGF and the
various clinicopathological factors were examined using the
x2 test. The mean value and SD of PCNA LIs were calculated
and compared with clinicopathological factors using the
Student’s t test.
Case Age Sex Sm. Al. Dif. TNM Stage Rec. p-AKT E-cadherin VEGF PCNA I DOF/Status
82 56 M No No Well T2N1M0 III Neg. Pos. Pos. 39 60/L
83 59 M Yes No Mod. T4N1M0 IV Neg. Neg. Neg. 50 20/D
84 63 M Yes No Well T1N0M0 I Pos. Neg. Pos. 81 58/L
Al., alcohol drinking habit; D, dead; Dif., differentiation; DOF, duration of follow up; F, female; L, living; M, male; Mod., moderate; Neg., negative; p-Akt,
phosphorylated Akt; PCNA I, PCNA labelling index; Pos., positive; R, recurred; Rec., recurrence; Sm., smoking habit; VEGF, vascular endothelial growth factor.
Table 1 Continued
Table 2 Correlation between p-Akt, E-cadherin, PCNA, and VEGF expression and clinicopathological features
Variables N p-AKT+ n (%) E-cad+ n (%) Mean (SD) PCNA LI VEGF+ n (%)
Age
,60 42 14 (33.3%) 19 (45.2%) 56.5 (17.2) 27 (64.3%)
>60 42 15 (35.7%) 21 (50.0%) 57.5 (20.6) 30 (71.4%)
Sex
Male 62 23 (37.1%) 30 (48.4%) 58.1 (19.3) 41 (66.1%)
Female 22 6 (27.3%) 10 (45.5%) 53.7 (17.3) 16 (72.7%)
Smoking
Yes 40 15 (37.5%) 15 (37.5%) 58.1 (19.3) 26 (65.0%)
No 44 14 (31.8%) 25 (56.8%) 56.0 (18.5) 31 (70.5%)
Alcohol
,1 B/w 39 12 (30.8%) 20 (51.3%) 57.4 (21.0) 24 (61.5%)
>1 B/w 45 17 (37.8%) 20 (44.4%) 56.7 (17.0) 33 (73.3%)
Differentiation
Well 61 19 (31.1%) 32 (52.5%) 56.0 (19.8) 42 (68.9%)
Moderate/Poor 23 10 (43.5%) 8 (34.8%) 59.7 (16.2) 15 (65.2%)
Tumour size
T1/T2 51 14 (27.5%) 24 (47.1%) 56.2 (17.1) 36 (70.6%)
T3/T4 33 15 (45.5%) 16 (48.5%) 58.3 (21.4) 21 (63.6%)
LN metastasis
Positive 29 15 (51.7%)* 9 (31.0%)* 58.2 (19.4) 22 (75.9%)
Negative 55 14 (25.5%)* 31 (56.4%)* 56.3 (18.6) 35 (63.6%)
Clinical stage
I/II 42 9 (21.4%) * 21 (45.2%) 57.2 (17.4) 28 (66.7%)
III/IV 42 20 (47.6%)* 19 (50.0%) 56.8 (20.4) 29 (69.0%)
Recurrence
Yes 29 13 (44.8%) 10 (34.5%) 53.9 (19.4) 21 (72.4%)
No 55 16 (29.1%) 30 (54.5%) 58.6 (18.5) 36 (65.5%)
*p,0.05, x2 test.
1 B/w, 1 bottle (360 ml; 25% alcohol)/week; LN, lymph node; p-Akt, phosphorylated Akt; PCNA LI, proliferating cell nuclear antigen labelling index; VEGF,
vascular endothelial growth factor.
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Survival curves were calculated using the Kaplan–Meier
method and analysed using the log rank test. The expression
of PCNA was classified as high at > 60% and low at , 60%
for the Kaplan–Meier method. Deaths caused by OSCC were
considered as outcomes and all deaths from other causes
were censored. The roles of each identified prognostic factor
(by univariate analysis) and combined effects (by multi-
variate analysis) were explored using the Cox proportional
hazards survival analysis model. In the univariate analysis,
the hazards ratio and its 95% confidence interval were
calculated for each variable. Forward and backward stepwise
procedures were used to identify the combination of factors
that was important in the prediction of prognosis. All
statistical analyses were considered significant when the p
value was less than 0.05. Statistical analyses were performed
using SPSS version 11.5.
RESULTS
Correlation between p-Akt, E-cadherin, PCNA, and
VEGF expression and clinicopathological factors
Table 2 shows the association of several clinicopathological
factors with p-Akt, E-cadherin, PCNA, and VEGF expression.
P-Akt expression was positive in 29 cases (fig 1A). p-Akt
staining significantly correlated with lymph node metastasis
and clinical stage (p , 0.05). Patients with a smoking habit,
poor differentiation, large tumour size, and recurrence
tended to show higher p-Akt expression, but the result was
not significant.
E-cadherin was expressed in 40 cases and correlated with
lymph node metastasis (p , 0.05). The mean PCNA LI was
57.0 and VEGF was expressed in 57 cases. There was no
significant correlation between PCNA and VEGF expression
and clinicopathological factors.
Correlation between p-Akt expression and the
expression of E-cadherin, VEGF, and PCNA
Table 3 shows that p-AKT expression was significantly higher
in cases with high expression of E-cadherin than in those
with low expression (p = 0.001). Cases with high VEGF or
PCNA expression had higher p-Akt expression, but this was
not significant (p = 0.143 and p = 0.091, respectively).
Survival analysis
Univariate Cox proportional hazards survival analysis of 84
OSCCs showed that the following factors indicated a worse
prognosis (table 4): poor differentiation (p = 0.039), large
tumour size (p = 0.003), high clinical stage (p = 0.0002),
positive lymph node metastasis (p = 0.003), recurrent




Negative Positive p Value*
E-cadherin expression
Negative 44 19 (22.6%) 25 (29.8%) 0.001
Positive 40 36 (42.9%) 4 (4.8%)
Mean (SD) PCNA LI 54.5 (18.9) 61.8 (18.1) 0.091
VEGF expression
Negative 27 21 (25.0%) 6 (7.1%) 0.143
Positive 57 34 (40.5%) 23 (27.4%)
*Chi square test.
p-Akt, phosphorylated Akt; PCNA LI, proliferating cell nuclear antigen labelling index; VEGF, vascular endothelial
growth factor.
Figure 1 Immunohistochemical
staining in oral squamous cell
carcinoma. (A) Positive expression of
phosphorylated Akt (original
magnification,6200); (B) positive
expression of E-cadherin (original
magnification,6200); (C) high
expression of PCNA (original
magnification,6100); (D) positive
expression of VEGF (original
magnification,6200).
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disease (p = 0.007), high p-Akt expression (p = 0.001),
low E-cadherin expression (p = 0.021), and high PCNA LI
(p = 0.049). Figure 2A–F shows the survival curves calcu-
lated by the Kaplan–Meier method and analysed using the
log rank test. They show that the survival of patients with
high p-Akt expression was significantly worse than that of
those with low p-Akt expression (p = 0.0005). Survival was
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Figure 2 Survival curves of patients with oral squamous cell carcinoma according to (A) phosphorylated Akt (p-Akt) expression, (B) p-Akt expression
in T1 and T2 tumours, (C) E-cadherin expression, (D) lymph node (LN) metastasis, (E) tumour size, and (F) clinical stage (Kaplan–Meier method).
Table 4 Univariate analysis of survival in 84 patients with OSCC according to the Cox proportional hazards model
Variables Hazards ratio 95% CI p Value
Age ( 60/.60) 1.954 0.954 to 3.999 0.067
Sex (M/F) 0.732 0.317 to 1.694 0.3467
Smoking (yes/no) 2.030 0.992 to 4.156 0.053
Alcohol (,1 B/w/>1 B/w) 1.192 0.596 to 2.385 0.619
Differentiation (well/moderate, poor) 2.106 1.037 to 4.275 0.039
Tumour size (T1, T2/T3, T4) 2.899 1.426 to 5.895 0.003
LN metastasis (positive/negative) 2.875 1.429 to 5.784 0.003
Clinical stage (I, II/III,IV) 3.383 1.557 to 7.352 0.002
Recurrence (yes/no) 2.595 1.291 to 5.214 0.007
p-AKT expression (+/2) 3.219 1.594 to 6.505 0.001
E-cadherin expression (+/2) 0.414 0.196 to 0.875 0.021
VEGF expression (+/2) 1.805 0.780 to 4.176 0.168
PCNA LI 1.022 1.000 to 1.044 0.049
1 B/w,1 bottle (360 ml; 25% alcohol)/week; CI, confidence interval; F, female; LN, lymph node; M, male; OSCC, oral squamous cell carcinoma; p-Akt,
phosphorylated Akt; PCNA LI, proliferating cell nuclear antigen labelling index; VEGF, vascular endothelial growth factor.
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T2 tumours (p = 0.0006). Multivariate Cox proportional
hazards survival analysis revealed that pAkt expression and
clinical stage were independent prognostic factors (table 5).
DISCUSSION
To establish appropriate therapeutic modalities for OSCC, an
accurate assessment of the factors affecting tumour progres-
sion and patient prognosis is crucial. Although the conven-
tional TNM staging system is useful for OSCC classification,
the outcome is poor for patients even in the low stage (I and
II) groups. Therefore, several molecular markers used for
OSCC classification have been investigated, but none showed
great value in predicting patient prognosis.
Akt is a central player in the signal transduction pathways
activated in response to growth factors or insulin, and is
thought to contribute to several cellular functions including
cell growth, proliferation, apoptosis, invasion, and angiogen-
esis. Recently, several important publications have described
novel mechanisms of regulating Akt. Alteration of Akt
expression and activity is associated with several human
cancers including glioblastoma, and ovarian, breast, pan-
creatic, and lung cancers.21
‘‘Phosphorylated Akt expression correlated with lymph
node metastasis, the clinical stage of which remains a
significant prognostic variable in oral squamous cell
carcinoma’’
In our study, we used immunohistochemistry to analyse p-
Akt and Akt related biological factors known to be involved
in tumour progression, such as E-cadherin (associated with
cancer invasion), VEGF (tumour angiogenesis), and PCNA
(marker of tumour proliferative activity).
The reported incidence of p-Akt expression varied from
26% in prostate cancer27 to 66% in both melanomas30 and
head and neck squamous cell carcinomas.31 We found p-Akt
expression in 34.5% of OSCCs. However, our threshold for
positive expression was 20%, higher than the 10% used in
Gupta’s study.31 If Gupta et al had used our 20% threshold,
they would have found p-Akt expression in 23.7% of their
cases, which is similar to our result.
p-Akt expression correlated with lymph node metastasis,
the clinical stage of which remains a significant prognostic
variable in OSCC. Gupta et al reported that p-Akt staining was
not associated with T stage, N stage, or differentiation of
disease. However, the number of cases in their study (38) was
too small to carry out meaningful multivariate analysis. In
pancreatic cancers, Schlieman et al showed that p-Akt
expression correlated with higher histological tumour
grade.32 Because reports on the relations between p-Akt
expression and clinicopathological factors are rare, an
additional larger scale study would be needed to elucidate
this association.
E-cadherin expression is closely related to lymph node
metastasis. Several reports have shown that E-cadherin
expression is significantly correlated with lymph node
metastasis in OSCC.33 34
There was no significant correlation between VEGF and
PCNA expression and the clinicopathological factors.
Our study suggests a significant inverse correlation
between p-Akt and E-cadherin expression in OSCC. This is
the first study to demonstrate such an association. Akt
activation represses E-cadherin gene transcription by upre-
gulation of the transcription repressors SNAIL and SIP1.25
In our study, univariate and multivariate survival analysis
showed that p-Akt and clinical stage were independent
prognostic factors in OSCC. The multiple activities of Akt,
such as enhancement of proliferation, growth, antiapoptosis,
invasiveness, and angiogenesis, endow OSCC with micro-
invasiveness at the resected margin and promote the invasion
and recurrence of cancer. Thus, high p-Akt expression in a
patient with OSCC would warrant a more radical mode of
treatment.
In conclusion, our study revealed that Akt activation is a
significant prognostic indicator for OSCC and may provide a
new method of treatment of OSCC. The inhibition of Akt is a
possible molecular approach to the treatment of OSCC.
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